Q3 Revenue Climbs to $32.9M as ETUARY Sales Grow, 2026 Outlook Reaffirmed
GYRE is trading near its 52-week low of $3.97 (1.0% above the low) on elevated volume (1.8× avg).
Summary
Q3 revenue came in at $32.9M with a GAAP basic loss of $0.04 per share, and management kept full-year 2026 revenue guidance at $100.5M–$111.0M. The quarter's net loss was $2.5M versus $1.9M net income a year earlier, as operating expenses rose $3.2M. The growth engine is ETUARY, which sold $31.4M versus $27.7M a year earlier, though Etorel and Contiva declined. Liquidity is the soft spot: cash and investments fell to $98.8M from $116.1M at Dec. 31, 2025, a $17.3M drop the company attributes mainly to lower short-term investments. The stock sits near its 52-week low, so the affirmed outlook removes a near-term downside risk but doesn't change the story. The real swing factor is China's NMPA decision on F351, expected by end-2026 or Q1 2027.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — Gyre's Q3 2026 net loss was $2.5M versus $1.9M net income a year earlier, as operating expenses rose $3.2M.
At the time of this announcement, GYRE was trading at $4.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $425.2M. The 52-week trading range was $3.97 to $9.14. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.